REDWOOD CITY, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its ...
Amid the unprecedented challenges presented by the COVID-19 pandemic, a once obscure enzyme found itself in the spotlight: reverse transcriptase. As laboratories worldwide rushed to develop reliable ...
One of the hallmarks of many DNA polymerases is that they proofread as they copy DNA, ensuring high-fidelity duplicates of an organism’s genome. This error-checking ability is missing from enzymes ...
The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...
BRANFORD, CT / ACCESSWIRE / May 28, 2024 / RNAConnect, a pioneering life science tools company, officially announced the commercial launch of UltraMarathonRT™ (uMRT), a next-generation, ...
Bacteria defend themselves from viral infection using diverse immune systems, many of which sense and target foreign nucleic acids. Defense-associated reverse transcriptase (DRT) systems provide an ...
If you're getting treated for an HIV infection, your doctor may suggest a type of drug called an NRTI. It's short for "nucleoside/nucleotide reverse transcriptase ...
On the third day of the J.P. Morgan Healthcare Conference, Arbor Biotechnologies and Vertex Pharmaceuticals announced that they would be expanding into reverse transcription-based in vivo genetic ...
RNA polymerases are sloppy. A retrovirus with an RNA genome, which is copied into DNA by a reverse transcriptase, is prone to mutations because the enzyme lacks the 3’ to 5’ proofreading capability of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results